Nanosonics Ltd - Company Profile
Powered by 
All the sales intelligence you need on Nanosonics Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Nanosonics Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Nanosonics Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Nanosonics Ltd (Nanosonics) is an Australian company specializing in infection prevention solutions. The company's main activities involve the development and commercialization of automated disinfection technologies. Its major product is the trophon device, which is designed for high-level disinfection of ultrasound probes. The company markets its products under the brand name Trophon.Nanosonics' products are used by healthcare institutions to prevent infections, enhancing patient safety and care quality. The company collaborates with various channel partners to distribute its products globally. The company operates in North America, Europe, the Middle East and the Asia Pacific region. Nanosonics is headquartered in Sydney, New South Wales, Australia.
Headquarters
Australia
Address
Level 1 Building A, 7-11 Talavera Road, Macquarie Park, Sydney, New South Wales, 2113
Website
www.nanosonics.com.au
Telephone
61 2 80631600
No of Employees
470
Industry
Medical Equipment
Ticker Symbol & Exchange
NAN (ASX)
Revenue (2025)
$131.0M
16.8%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
59.4%
(2025 vs 2024)
Market Cap*
$636.4M
Net Profit Margin (2025)
XYZ
36.4%
(2025 vs 2024)
* As of and is in US$
Nanosonics Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Ultrasound Probe Reprocessing Solutions: |
| trophon2 |
| AuditPro |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In March 2025, the company received FDA De Novo Clearance for CORIS Innovation. |
| 2025 | New Products/Services | In July 2025, the company launched Next Generation Trophon 3 and Trophon2 Plus Software Upgrade. |
| 2025 | Regulatory Approval | In August, the company received US FDA Clearance for Next Generation Trophon Technology. |
Competitor Comparison
| Key Parameters | Nanosonics Ltd | Siemens Healthineers AG | GE HealthCare Technologies Inc | Ecolab Inc | Tristel plc |
|---|---|---|---|---|---|
| Headquarters | Australia | Germany | United States of America | United States of America | United Kingdom |
| City | Sydney | Forchheim | Chicago | Saint Paul | Snailwell |
| State/Province | New South Wales | Bayern | Illinois | Minnesota | England |
| No. of Employees | 470 | 72,000 | 53,000 | 48,000 | 265 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Kavanagh | Managing Director; Chief Executive Officer; President | Executive Board | 2013 | - |
| Jason Burriss | Chief Financial Officer | Senior Management | 2023 | - |
| Rod Lopez | Chief Operating Officer; Regional President-Asia Pacific | Senior Management | 2019 | - |
| Sunny Pillai | Chief Information Officer | Senior Management | 2022 | - |
| Matthew Lipscombe | Chief Marketing Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer